187 related articles for article (PubMed ID: 38386170)
61. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
63. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
64. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
65. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
[TBL] [Abstract][Full Text] [Related]
66. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
67. Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients.
Wang M; Li J; Xu S; Li Y; Li J; Yu J; Tang X; Zhu H
Cancer Med; 2023 Mar; 12(5):5352-5363. PubMed ID: 36271595
[TBL] [Abstract][Full Text] [Related]
68. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
69. The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.
Meng LF; Huang JF; Luo PH; Huang SX; Wang HL
Invest New Drugs; 2022 Aug; 40(4):810-817. PubMed ID: 35412172
[TBL] [Abstract][Full Text] [Related]
70. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
71. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
72. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
[TBL] [Abstract][Full Text] [Related]
73. Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer.
Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Cancer; 2023 Aug; 129(15):2297-2307. PubMed ID: 37021822
[TBL] [Abstract][Full Text] [Related]
74. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
75. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
[TBL] [Abstract][Full Text] [Related]
76. PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Qin Y; Jiang L; Yu M; Li Y; Zhou X; Wang Y; Gong Y; Peng F; Zhu J; Liu Y; Xu Y; Zhou L; Lu Y; Huang M
Sci Rep; 2020 Sep; 10(1):16150. PubMed ID: 32999345
[TBL] [Abstract][Full Text] [Related]
77. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
[No Abstract] [Full Text] [Related]
79. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
80. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
